Covid-19 roundup: No­vavax fi­nal­ly re­ceives the go-ahead in Eu­rope for its vac­cine; CDC strug­gles to track Omi­cron

The long wait for No­vavax’s promis­ing Covid-19 vac­cine will soon be over for Eu­ro­peans.

The Eu­ro­pean Med­i­cines Agency on Mon­day rec­om­mend­ed grant­i­ng a con­di­tion­al mar­ket­ing au­tho­riza­tion for No­vavax’s shot, to be known as Nu­vax­ovid, to pre­vent Covid-19 for all those over the age of 18. And lat­er Mon­day morn­ing, the Eu­ro­pean Com­mis­sion grant­ed that au­tho­riza­tion.

Clin­i­cal tri­als of the two-shot vac­cine, with each jab tak­en three weeks apart, showed it was safe and of­fered strong ef­fi­ca­cy, but the EMA warned that the vac­cine has not been test­ed against some vari­ants of con­cern like Omi­cron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER